Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp (ADPT): 7 pipeline candidates · ~73 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
73.4 months
D/E 1.30 · 0% dilution
Lead: Approved
7 candidates
N/A
0 buys · 81 sells (180d)
A transparent, data-derived signal for Adaptive Biotechnologies Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.7B
Cash
$77.6M
Quarterly Burn
$9.5M
Runway
73.4 mo
Revenue
$70.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
295
Total value held
$2.04B
| Holder | Shares | Value |
|---|---|---|
| viking global investors lp | 29,993,708 | $416.3M |
| blackrock, inc. | 13,303,025 | $184.6M |
| vanguard capital management llc | 12,188,288 | $169.2M |
| westfield capital management co lp | 5,436,718 | $75.5M |
| vanguard portfolio management llc | 4,491,474 | $62.3M |
| wellington management group llp | 3,857,422 | $53.5M |
| geode capital management, llc | 3,636,054 | $50.5M |
| goldman sachs group inc | 3,242,077 | $45.0M |
| state street corp | 3,227,245 | $44.8M |
| ameriprise financial inc | 3,017,341 | $41.9M |
Showing top 10 of 295 institutional holders of Adaptive Biotechnologies Corp. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Adaptive Biotechnologies Corp's pipeline?
Adaptive Biotechnologies Corp (ADPT) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Adaptive Biotechnologies Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Adaptive Biotechnologies Corp has approximately 73.4 months of cash runway.
What is Adaptive Biotechnologies Corp's market capitalization?
Adaptive Biotechnologies Corp's market capitalization is approximately $2.7B.
Who is the CEO of Adaptive Biotechnologies Corp?
Mr. Chad M. Robins M.B.A. is the chief executive officer of Adaptive Biotechnologies Corp (ADPT).
Get the full picture on Adaptive Biotechnologies Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.